The return of biotech

Avalon Ventures has reversed its stance on the sector and is teaming up with GlaxoSmithKline to fund up to 10 new companies

1 January 2014•3 mins read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.